1
|
Chu T, Tang Y, Wang H, Qi J, Zhao Y, Pan T, Tang X, Qiu H, Fu C, Ruan C, Wu DP, Han Y. Efficacy of recombinant factor VIIa for severe bleeding complicated by platelet transfusion refractoriness in patients with hematologic malignancies. Thromb Res 2017; 160:14-18. [PMID: 29080548 DOI: 10.1016/j.thromres.2017.10.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Revised: 09/11/2017] [Accepted: 10/19/2017] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Severe bleeding with platelet transfusion refractoriness (PTR) is a common complication associated with reduced survival in patients with hematologic malignancies. The present study aimed to evaluate the efficacy of recombinant factor VIIa (rFVIIa) for severe bleeding complicated by PTR. MATERIALS AND METHODS Sixty-four patients suffering from severe bleeding with PTR hospitalized in our center between September 2012 and December 2016 were enrolled in this study. Thirty-two patients received rFVIIa (rFVIIa group) and other conventional hemostatic treatments, while the other 32 patients received conventional hemostatic treatments other than rFVIIa (control group). RESULTS The baseline parameters of patients before treatment were similar in both groups. The total response rates to hemostatic treatment at 24h and 48h were significantly higher in the rFVIIa group compared with the control group (p=0.014, p=0.020, respectively). Significantly more patients in the rFVIIa group achieved complete responses (CR) at 24h (p=0.031), 48h (p=0.039), and 72h (p=0.021) compared with the control group. The bleeding score (p=0.029), time to control bleeding (p=0.034), and activated partial thromboplastin time (p=0.021) after hemostatic treatment were significantly lower in the rFVIIa group compared with the control group. Patients who achieved a CR to rFVIIa had a significant survival advantage compared with those with a partial response/no response (p=0.020). No complications with venous or arterial thromboembolism were observed during treatment. CONCLUSIONS rFVIIa may provide effective and safe hemostasis in patients suffering from severe bleeding and PTR.
Collapse
Affiliation(s)
- Tiantian Chu
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yaqiong Tang
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Hong Wang
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China
| | - Jiaqian Qi
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Ying Zhao
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Tingting Pan
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiaowen Tang
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
| | - Huiying Qiu
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
| | - Chengcheng Fu
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
| | - Changgeng Ruan
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
| | - De-Pei Wu
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
| | - Yue Han
- Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
| |
Collapse
|
2
|
Franchini M, Lippi G, Guidi GC. The use of recombinant activated factor VII in platelet-associated bleeding. Hematology 2013; 13:41-5. [DOI: 10.1179/102453308x315816] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Affiliation(s)
- Massimo Franchini
- Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
| | - Giuseppe Lippi
- Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona, Italy
| | - Gian Cesare Guidi
- Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona, Italy
| |
Collapse
|
3
|
McCarthy GC, Allen TK, Habib AS. Pulmonary embolism after administration of recombinant activated Factor VII for major obstetric hemorrhage. J Clin Anesth 2012; 24:508-9. [PMID: 22986324 DOI: 10.1016/j.jclinane.2011.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2011] [Revised: 09/05/2011] [Accepted: 09/06/2011] [Indexed: 11/26/2022]
|
4
|
Abstract
Proteases are an expanding class of drugs that hold great promise. The U.S. FDA (Food and Drug Administration) has approved 12 protease therapies, and a number of next generation or completely new proteases are in clinical development. Although they are a well-recognized class of targets for inhibitors, proteases themselves have not typically been considered as a drug class despite their application in the clinic over the last several decades; initially as plasma fractions and later as purified products. Although the predominant use of proteases has been in treating cardiovascular disease, they are also emerging as useful agents in the treatment of sepsis, digestive disorders, inflammation, cystic fibrosis, retinal disorders, psoriasis and other diseases. In the present review, we outline the history of proteases as therapeutics, provide an overview of their current clinical application, and describe several approaches to improve and expand their clinical application. Undoubtedly, our ability to harness proteolysis for disease treatment will increase with our understanding of protease biology and the molecular mechanisms responsible. New technologies for rationally engineering proteases, as well as improved delivery options, will expand greatly the potential applications of these enzymes. The recognition that proteases are, in fact, an established class of safe and efficacious drugs will stimulate investigation of additional therapeutic applications for these enzymes. Proteases therefore have a bright future as a distinct therapeutic class with diverse clinical applications.
Collapse
|
5
|
The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2009; 7:24-8. [PMID: 19290076 DOI: 10.2450/2008.0015-08] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 04/22/2008] [Revised: 10/06/2008] [Indexed: 11/21/2022]
|
6
|
William BM. Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor. Blood Coagul Fibrinolysis 2008; 19:327-8. [PMID: 18469559 DOI: 10.1097/mbc.0b013e3283001d49] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
7
|
El Kinge ARD, Mahfouz RA, Shamseddine AI, Taher AT. Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder. Blood Coagul Fibrinolysis 2007; 18:577-9. [PMID: 17762536 DOI: 10.1097/mbc.0b013e3281eec9a1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrhages in hemophiliac patients with inhibitors and in acquired hemophilia patients. Recombinant activated factor VII use has also been considered for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. The myeloproliferative disorders are a group of clonal hematologic diseases where, frequently, abnormal platelet function is considered a hallmark. This is the first case report addressing the clinical benefit of off-label use of recombinant activated factor VII in an attempt to control intractable bleeding in a patient with a myeloproliferative disorder after splenectomy.
Collapse
Affiliation(s)
- Abdul Rahman D El Kinge
- Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
| | | | | | | |
Collapse
|
8
|
STEINER MARIEE, KEY NIGELS. Use of recombinant activated factor VII in the management of medical and surgical bleeding: a critical review. ACTA ACUST UNITED AC 2006. [DOI: 10.1111/j.1778-428x.2006.00033.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost 2006; 12:115-6. [PMID: 16444446 DOI: 10.1177/107602960601200120] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The case of a 41-year-old woman with Glanzmann's thrombasthenia who underwent double dental extraction is presented. In the past, treatments with desmopressin (DDAVP) and tranexamic acid had often unsuccessful efficacy to stop or decrease bleeding. After ineffective DDAVP administration, the removal was performed successfully with recombinant activated factor VII (rFVIIa) infusion. rFVIIa infusion after DDAVP administration could be useful in patients with Glanzmann's thrombasthenia in which DDAVP and tranexamic acid weren't always effective.
Collapse
Affiliation(s)
- Vincenzo Trapani Lombardo
- Hemophilia Center--Thrombosis and Hemostasis Service, Hematology Department, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
| | | |
Collapse
|
10
|
Leblebisatan G, Sasmaz I, Antmen B, Kilinc Y, Sizmaz S, Yagmur M. A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision. Haemophilia 2006; 12:187-9. [PMID: 16476096 DOI: 10.1111/j.1365-2516.2006.01191.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- G Leblebisatan
- Department of Pediatric Hematology, Cukurova University Medical Faculty, Adana, Turkey.
| | | | | | | | | | | |
Collapse
|
11
|
Barcelona SL, Thompson AA, Coté CJ. Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions. Paediatr Anaesth 2005; 15:814-30. [PMID: 16176309 DOI: 10.1111/j.1460-9592.2004.01549.x] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Sandra L Barcelona
- Department of Anesthesiology, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
| | | | | |
Collapse
|
12
|
Geddis AE. The molecular basis of congenital thrombocytopenias: insights into megakaryopoiesis. ACTA ACUST UNITED AC 2005; 10 Suppl 1:299-305. [PMID: 16188691 DOI: 10.1080/10245330512331390401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Amy E Geddis
- Department of Pediatrics, University of California, San Diego, USA
| |
Collapse
|
13
|
Conesa V, Navarro-Ruiz A, Borrás-Blasco J, Mompel A, Gómez A, González M. Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report. Int J Hematol 2005; 81:75-6. [PMID: 15717694 DOI: 10.1532/ijh97.e0415] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A 50-year-old woman was admitted to the emergency room. An appendectomy was done. On the sixth day the patient's general state deteriorated and she became somnolent with jaundice due to distal obstructive choledocholithiasis. The results of laboratory tests were platelets 12 x 10(9)/L, prothrombin time 13 seconds, international normalized ratio 1.19, activated partial thromboplastin time 31.8 seconds, and fibrinogen 8.78 g/L. There was no evidence of disseminated intravascular coagulation. In view of the patient's clinical condition, surgery was considered to be indicated. Because it was a life-threatening situation and at the time there was no platelet concentrate available for immediate transfusion, she was treated with a single dose of recombinant factor VIIa (rFVIIa) (60 microg/kg). The dose of 60 microg/kg was selected on the basis of experience with rFVIIa in the treatment of hemophilic patients. In this case, use of rFVIIa was a valid alternative to control the bleeding in a patient with thrombocytopenia. However, despite the efficacy of the treatment, it should not be forgotten that it was used because of the unavailability of platelets and that we were dealing with a life-threatening situation. Clinical trials should be carried out to verify the safety, effectiveness, and efficiency of rFVIIa in these cases.
Collapse
Affiliation(s)
- Venancio Conesa
- Hematology Service, Hospital General Universitario de Elche, Elche, Alicante, Spain
| | | | | | | | | | | |
Collapse
|
14
|
Kaw LL, Coimbra R, Potenza BM, Garfin SR, Hoyt DB. The use of recombinant factor VIIa for severe intractable bleeding during spine surgery. Spine (Phila Pa 1976) 2004; 29:1384-7; discussion 1388. [PMID: 15187645 DOI: 10.1097/01.brs.0000127189.66567.ab] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
STUDY DESIGN A report on the use of recombinant activated factor VII in 4 patients who developed severe intractable bleeding and coagulopathy during spine surgery. OBJECTIVE To describe the role of recombinant activated factor VII for hemostasis during spine surgery. SUMMARY OF BACKGROUND DATA Recombinant activated factor VII is indicated for the treatment of bleeding episodes and the prevention of bleeding during surgery in patients with hemophilia with inhibitors. However, its use in adults undergoing spine surgery has not yet been reported. METHODS Four patients who underwent multilevel spine surgery through an anterior approach incurred massive bleeding and subsequently became coagulopathic. Standard hemostatic techniques were performed and blood products were transfused. Persistence of the bleeding prompted the use of recombinant activated factor VII. RESULTS Treatment with recombinant activated factor VII led to an improvement in prothrombin time and partial thromboplastin time and brought about cessation in gross, nonsurgical bleeding intraoperatively. No clinically relevant thrombotic complications related to the drug were noted. CONCLUSIONS Recombinant activated factor VII is promising as an adjunctive hemostatic agent for patients with perioperative bleeding problems during spine surgery. Efficacy is seen even at low doses.
Collapse
Affiliation(s)
- Leoncio L Kaw
- Division of Trauma and Critical Care, Department of Surgery, University of California San Diego Medical Center, San Diego, California 92103-8896, USA
| | | | | | | | | |
Collapse
|
15
|
Abstract
Platelet dysfunction likely contributes to the pathophysiology of catastrophic hemorrhages in preterm neonates. In vitro studies have demonstrated that platelets of both term and preterm neonates are hyporesponsive to a variety of agonists. In contrast,template bleeding times of term neonates are shorter than those from adults. Very little is known about this and other tests of primary hemostasis in premature and sick neonates in the neonatal intensive care unit (NICU). This article covers the current knowledge of platelet function in preterm and term neonates and review show new agents (such as recombinant thrombopoietin and recombinant factor VIIa) may enhance neonatal platelet function.
Collapse
Affiliation(s)
- Matthew A Saxonhouse
- Division of Neonatology, Department of Pediatrics, University of Florida, College of Medicine, P.O. Box 100296, 1600 SW Archer Road, Gainesville, FL 32610, USA.
| | | |
Collapse
|
16
|
Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, de Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. BJOG 2004; 111:284-7. [PMID: 14961895 DOI: 10.1111/j.1471-0528.2004.00058.x] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Françoise Boehlen
- Haemostasis Unit, Division of Angiology and Haemostasis, Department of Medicine, University Hospitals, 1211 Geneva 4, Switzerland
| | | | | | | | | | | |
Collapse
|
17
|
Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004; 16:15-22. [PMID: 14758109 DOI: 10.1097/00008480-200402000-00005] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW To review the defined syndromes of inherited thrombocytopenia and discuss new genetic data for several disorders that shed light on the process of megakaryopoiesis. RECENT FINDINGS The genes responsible for several inherited thrombocytopenias have been recently discovered, including congenital amegakaryocytic leukemia, amegakaryocytic thrombocytopenia with radio-ulnar synostosis, familial platelet syndrome with predisposition to acute myelogenous leukemia, Paris-Trousseau, Wiskott-Aldrich syndrome, and the May-Hegglin, Sebastian, Epstein, and Fechner syndromes. These clinical syndromes, combined with studies in mouse and in vitro models, reveal the importance of these genes for normal hematopoiesis. SUMMARY Although inherited syndromes of thrombocytopenia are rare, characterization of mutations in these disorders has contributed greatly to our understanding of megakaryocyte and platelet development. A systematic registry of congenitally thrombocytopenic individuals would almost certainly lead to new genetic discoveries.
Collapse
Affiliation(s)
- Amy E Geddis
- Department of Pediatrics, University of California, San Diego, USA.
| | | |
Collapse
|